Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended 31 March 2018
Issued Date: 25 April 2018
GSK reported Q1 2018 results with a focus on constant exchange rate (CER) growth across all three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The quarter was significantly impacted by currency movements, particularly the strength of Sterling, and a major strategic agreement to acquire full ownership of the Consumer Healthcare business from Novartis.
Key Financial Metrics
| Metric | Q1 2018 | Q1 2017 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £7,222m | £7,384m | -2% | +4% |
| Total Operating Profit | £1,240m | £1,718m | -28% | -15% |
| Adjusted Operating Profit | £1,923m | £1,979m | -3% | +9% |
| Adjusted Operating Margin | 26.6% | 26.8% | -0.2 pp | +1.3 pp |
| Total EPS | 11.2p | 21.4p | -48% | -33% |
| Adjusted EPS | 24.6p | 25.0p | -2% | +11% |
| Free Cash Flow | £324m | £650m | -50% | N/A |
| Net Debt | £13,377m | £13,743m | N/A | N/A |
Note: AER = Actual Exchange Rate; CER = Constant Exchange Rate; pp = percentage points.
Segment Performance
- Pharmaceuticals: Turnover £4.0bn (-4% AER, +2% CER). Driven by HIV growth (Triumeq, Tivicay) and new respiratory launches (Trelegy, Nucala), offset by declines in Seretide/Advair.
- Vaccines: Turnover £1.2bn (+7% AER, +13% CER). Growth driven by Shingrix and Bexsero.
- Consumer Healthcare: Turnover £2.0bn (-3% AER, +2% CER). Strong performance in Oral Health and Pain Relief offset by generic competition to Transderm Scop.
Material Changes vs. Prior Period
- Accounting Charges: Total EPS declined 48% AER primarily due to a £495m revaluation charge related to the Consumer Healthcare put option following the agreement to buy out Novartis' stake. This is a non-cash accounting adjustment.
- Free Cash Flow: Dropped 50% to £324m, largely due to a £317m milestone payment to Novartis for Bexsero sales and a £80m dividend to non-controlling interests.
- Revenue Mix: While reported turnover fell 2% due to currency, underlying business growth (CER) was positive at 4%, indicating operational resilience despite Sterling strength.
- Cost Control: Adjusted operating margin improved by 1.3 percentage points on a CER basis, reflecting cost discipline and restructuring savings.
Guidance, Outlook, and Risks
2018 Guidance
GSK maintains its guidance for Adjusted EPS growth of 4% to 7% at CER for 2018, contingent on no substitutable generic competitor to Advair entering the US market in 2018.
- Scenario 1 (No Generic): Adjusted EPS growth 4-7% at CER.
- Scenario 2 (Mid-year Generic): Adjusted EPS expected to be flat to down 3% at CER. US Advair sales expected to decline to approx. £750m.
Dividend: A quarterly dividend of 19p was declared. The full-year 2018 dividend is expected to remain at 80p per share.
Key Risks and Contingencies
- Advair Generic Competition: The primary risk to 2018 earnings guidance is the potential launch of a generic version of Advair in the US, which could significantly impact respiratory sales.
- Currency Volatility: Strong Sterling continues to negatively impact reported turnover and earnings. Management estimates a potential 5% negative impact on full-year turnover and 8% on Adjusted EPS if current rates hold.
- Consumer Healthcare Buyout: The $13 billion acquisition of Novartis' stake is subject to shareholder approval and expected to close in June 2018.
- Legal and Tax: Ongoing litigation and tax investigations exist, though no material changes were reported since the 2017 Annual Report. The effective tax rate for 2018 is expected to be 19-20% on Adjusted profits.
Investor Verification Checklist
- Advair Status: Verify the current regulatory status and potential launch timeline for generic Advair in the US, as this is the critical variable for 2018 EPS guidance.
- Consumer Healthcare Deal: Confirm shareholder approval status and closing date for the Novartis buyout to assess future cash flow implications and consolidation of results.
- Currency Hedging: Review the company's hedging strategies given the significant negative impact of Sterling strength on reported metrics.
- Free Cash Flow Conversion: Monitor the recovery of free cash flow in subsequent quarters following the one-off Novartis milestone payment.
- Respiratory Portfolio Transition: Assess the sales trajectory of new products (Trelegy, Nucala) relative to the decline in legacy products (Advair, Seretide) to ensure the portfolio transition is on track.